Shaxlo Fayzullayeva

Shaxlo Fayzullayeva

Auto-generated profile, based on publicly available information

Shaxlo Fayzullayeva

Respublika ixtisoslashtirilgan ilmiy-amaliy kardiologiya tibbiyot markazi

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2025
Verified
Journal Article
Open access
PDF file
SFShaxlo Fayzullayeva
Shaxlo Fayzullayeva
GXGulnoza Xamidullayeva
Gulnoza Xamidullayeva
GAGuzal Abdullaeva
Guzal Abdullaeva
XYXafiza Yusupova
Xafiza Yusupova
Yurak-qon tomir kasalliklari (YuQTK) dunyo bo‘ylab kasallanish va o‘limning yetakchi sabablaridan biri hisoblanadi. Profilaktikaning samaradorligini oshirish maqsadida bir nechta dorivor moddalarni o‘z ichiga olgan polipill konsepsiyasi ilgari surilgan. Ushbu maqolada polipillning birlamchi va ikkilamchi profilaktikadagi o‘rni, uning afzalliklari va kamchiliklari tahlil qilinadi. Polipill birlamchi profilaktikada arterial gipertenziya, dislipidemiya va tromboz rivojlanishini oldini olish orqali YuQTK xavfini kamaytirishi mumkin. Ikkilamchi profilaktikada esa yurak xuruji va insult kabi holatlarning qayta yuzaga kelish ehtimolini pasaytirishga yordam beradi. Shuningdek, polipill dori qabul qilish tartibini yaxshilash va umumiy iqtisodiy xarajatlarni kamaytirish imkonini beradi.

23 January 2025 in CARDIOLOGY OF UZBEKISTAN
Verified
Journal Article
Open access
PDF file
ХАХ Атаниязов
Х Атаниязов
ГХГ Хамидуллаева
Г Хамидуллаева
ГАГ Абдуллаева
Г Абдуллаева
ХЮХ Юсупова
Х Юсупова
СБС Бекметова
С Бекметова
ШФШ Файзуллаева
Ш Файзуллаева
Background. Uncontrolled arterial hypertension in patients at high and very high cardiovascular risk remains a significant issue in modern medicine. Optimizing antihypertensive therapy using fixed or separate combinations of drugs represents a promising approach to improving blood pressure control and reducing the risk of cardiovascular complications. Materials and methods. The study included 40 patients (men and women) with grade I–III hypertension according to the ESC/ESH classification (2018). The mean age was 51.52 ± 9.43 years, and the average disease duration was 8.52 ± 6.64 years. Patients were divided into two groups: one received a fixed combination (lisinopril/amlodipine/rosuvastatin), and the other received a separate combination (perindopril/amlodipine and rosuvastatin). Treatment lasted for 3 months. Effectiveness was assessed using 24-hour blood pressure monitoring, applanation tonometry, echocardiography, ultrasound examination of brachiocephalic arteries, and laboratory analyses (lipid profile, glucose level, uric acid, and creatinine). Results. Both therapy regimens demonstrated high antihypertensive, organoprotective, and hypolipidemic effectiveness. However, patients receiving the fixed combination showed a more significant reduction in systolic and diastolic blood pressure, improved lipid profile, and decreased nighttime blood pressure variability. No adverse effects on metabolic profiles were observed. Conclusion. The fixed combination of drugs demonstrated superiority over the separate combination regimen, providing better blood pressure control and lipid profile improvement. These findings highlight the importance of selecting optimal therapy regimens for high cardiovascular risk patients and confirm the efficacy of fixed combinations in this patient group.